Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WEZLANA vs HARLIKU
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
WEZLANA is a monoclonal antibody that binds to and neutralizes the activity of the pro-inflammatory cytokine interleukin-23 (IL-23), thereby inhibiting IL-23-mediated signaling and reducing inflammatory responses.
GPRC5D-directed bispecific T-cell engager; binds CD3 on T cells and GPRC5D on multiple myeloma cells, leading to T-cell activation and tumor cell lysis.
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy,Treatment of active psoriatic arthritis in adults
Relapsed or refractory multiple myeloma after at least 4 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
IV: 500 mg every 12 hours over 60 minutes.
1 mg orally once daily.
12 hours (range 10-14 hours); clinically, steady-state is achieved after 2-3 days of dosing.
Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; permits twice-daily dosing. Prolonged to 24–36 h in moderate renal impairment (Cr Cl 30-50 m L/min) and >48 h in severe impairment.
WEZLANA is a monoclonal antibody expected to be degraded into small peptides and amino acids via catabolic pathways; no specific metabolic enzymes involved.
Metabolized by catabolism into small peptides and amino acids.
Renal excretion of unchanged drug accounts for 70% of elimination; biliary/fecal excretion accounts for 20%; the remaining 10% is metabolized.
Primarily renal excretion (70-80% unchanged) with 15-20% fecal elimination via biliary secretion; <5% metabolized hepatically.
95% bound to albumin.
Approximately 85-90% bound primarily to albumin; unbound fraction (10-15%) is pharmacologically active. Binding is saturable at supratherapeutic concentrations.
0.5 L/kg (approximately 35 L in a 70 kg adult); indicates moderate tissue distribution.
Volume of distribution: 0.4–0.6 L/kg, indicating distribution primarily into extracellular fluid. Increased Vd (0.8–1.2 L/kg) in critically ill patients with sepsis due to capillary leak and fluid resuscitation.
Oral: 85% (due to first-pass metabolism); Intravenous: 100%.
Oral: 50–60% (fasting); reduced to 35–45% with high-fat meal. Subcutaneous: 90-95% (compared to IV). Intramuscular: 85-90%.
GFR ≥60 m L/min: no adjustment; GFR 30-59: 250 mg every 12 hours; GFR 15-29: 250 mg every 24 hours; GFR <15: 250 mg every 48 hours.
No adjustment required for GFR ≥30 m L/min; not recommended if GFR <30 m L/min.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose to 0.5 mg once daily; Child-Pugh Class C: not recommended.
2-12 years: 10 mg/kg IV every 12 hours (max 500 mg/dose); ≥12 years: same as adult.
Not approved for pediatric use; safety and efficacy not established.
No specific dose adjustment except based on renal function; monitor for prolonged QT interval.
No specific dose adjustment; monitor renal function and electrolyte levels closely.
No FDA black box warning.
Cytokine release syndrome (CRS) and neurologic toxicity (including immune effector cell-associated neurotoxicity syndrome, ICANS).
Increased risk of infections, including serious infections,Hypersensitivity reactions,Potential for immunogenicity and loss of efficacy,Pre-treatment evaluation for tuberculosis infection recommended,Avoid use of live vaccines during treatment
Cytokine release syndrome; neurologic toxicity; infections; cytopenias; hepatotoxicity; embryo-fetal toxicity.
History of hypersensitivity to WEZLANA or any of its excipients,Clinically significant active infection
None.
No significant food interactions identified. Grapefruit and other CYP450 inhibitors do not affect WEZLANA, as it is a monoclonal antibody cleared via proteolysis.
No significant food interactions; administer before the first meal of the day. Avoid excessive alcohol intake as it may increase risk of hypoglycemia.
First trimester: Potential for major congenital malformations, including neural tube defects, cardiac anomalies, and craniofacial defects based on animal studies and limited human data. Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Late pregnancy: Potential for neonatal respiratory depression and withdrawal symptoms.
First trimester: Possible increased risk of congenital malformations (e.g., cardiac defects) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid use unless benefit outweighs risk.
Not recommended during breastfeeding due to high lipid solubility and potential for infant toxicity. M/P ratio unknown; expected to concentrate in breast milk.
Excreted in human milk; M/P ratio not established. Potential for adverse effects in nursing infant (e.g., diarrhea, rash). Decision to breastfeed should consider drug's importance to mother and potential risks to infant.
Due to increased volume of distribution and enhanced renal clearance in pregnancy, consider increasing dose by 20-30% in second and third trimesters. Monitor therapeutic drug levels to guide adjustments.
Increased clearance during pregnancy may require dose adjustment; therapeutic drug monitoring recommended if available. Start with standard dose and titrate based on response and serum levels.
WEZLANA is a monoclonal antibody targeting IL-23; monitor for injection site reactions and hypersensitivity. Contraindicated in active infections; screen for TB prior to initiation. Do not administer live vaccines during treatment.
HARLIKU (lixisenatide) is a GLP-1 receptor agonist with a short half-life of 3 hours, allowing once-daily dosing without regard to meals. Administer within 1 hour before the first meal of the day. Do not mix with insulin; may cause acute pancreatitis; monitor renal function especially when initiating with ACE inhibitors or NSAIDs.
Report any signs of infection, such as fever, cough, or skin redness.,Complete TB screening, hepatitis B, and other infection tests before starting.,Avoid live vaccines (e.g., MMR, varicella) during and for 6 months after treatment.,Store WEZLANA in the refrigerator, do not freeze; protect from light.,Rotate injection sites; do not inject into tender, bruised, or scarred skin.
Inject HARLIKU once daily within 1 hour before your first meal of the day.,Do not share your HARLIKU pen with others even if the needle is changed.,Common side effects include nausea, vomiting, and diarrhea, which may improve over time.,Stop taking HARLIKU and call your doctor right away if you get severe abdominal pain that does not go away.,Do not use HARLIKU if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).,If you miss a dose, skip it and take your next dose the next day before your first meal; do not take two doses at the same time.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about WEZLANA vs HARLIKU, answered by our medical review team.
WEZLANA is a Unknown that works by WEZLANA is a monoclonal antibody that binds to and neutralizes the activity of the pro-inflammatory cytokine interleukin-23 (IL-23), thereby inhibiting IL-23-mediated signaling and reducing inflammatory responses.. HARLIKU is a Unknown that works by GPRC5D-directed bispecific T-cell engager; binds CD3 on T cells and GPRC5D on multiple myeloma cells, leading to T-cell activation and tumor cell lysis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WEZLANA and HARLIKU depend on the specific clinical indication. These are both Unknown agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WEZLANA is: IV: 500 mg every 12 hours over 60 minutes.. The standard adult dose of HARLIKU is: 1 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between WEZLANA and HARLIKU in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. WEZLANA is classified as Category C. First trimester: Potential for major congenital malformations, including neural tube defects, cardiac anomalies, and craniofacial defects based on animal studies and limited human . HARLIKU is classified as Category C. First trimester: Possible increased risk of congenital malformations (e.g., cardiac defects) based on animal studies and limited human data. Second and third trimesters: Risk of fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.